Financial Data & APIs
Membership is Free
What are you waiting for? Sign up now!
Free Account Login
Click here to access your premium account
Username or email:
Benzinga - Feed Your Mind.
Best of Benzinga
Benzinga Fintech Awards
From The Press
Search by keyword...
Benzinga Staff Writer
August 30, 2013 8:59 AM
WSJ Report Suggests GE Capital Looking to Spin Off Retail Lending Unit
Shares of General Electric (NYSE: GE) are trading up almost 1.5 percent Friday morning following a WSJ report earlier suggesting the company could be ...
May 06, 2013 1:50 PM
TD Ameritrade's IMX Survey Declines to 5.31 in April
TD Ameritrade (NYSE: AMTD) issued April data for the Investor Movement Index Monday afternoon. The survey, released monthly on either the first or sec ...
April 25, 2013 6:20 PM
Amazon's Q1 Earnings Beat; Investors Disappointed in Outlook
Shares of Amazon.com (NASDAQ: AMZN) are down more than 2 percent after hours Thursday following a better-than-expected first-quarter earnings report. ...
April 08, 2013 5:40 PM
Ron Johnson Out as JC Penney Chief, Former CEO Named Successor
Shares of JC Penney (NYSE: JCP) are down approximately eight percent in Monday's after-hours trading session following a CNBC report Ron Johnson i ...
February 07, 2013 9:36 AM
Einhorn Demands Apple Preferred Shares, Says Greenlight Now Holds More Apple Than Ever Before
Shares of Apple (NASDAQ: AAPL) were up more than two percent in pre-market action Thursday morning following some action from activist investor David ...
November 23, 2012 9:09 AM
Research In Motion Shares Squeeze Higher as Traders Desperate for Liquid Plays
Research In Motion (NASDAQ: RIMM) shares are up more than 10 percent on very heavy volume (more than 2.8 million shares have already traded) in pre-ma ...
October 31, 2012 11:27 AM
Will the Mayans Curse the Gun Trade?
One of 2008's most popular investments, perhaps fueled by the election of Barack Obama, was the “gun trade.” There were several underlying assum ...
October 29, 2012 11:51 AM
Five Stocks for Hurricane Sandy
Hurricane Sandy is battering the East Coast and residents in New York City, New Jersey and Washington D.C. are hunkered down for at least several days ...
uniQure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B at ASH 2016
Takeda, Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS for CD30-Expressing Cutaneous T-Cell Lymphoma at ASH 2016
ArQule Announces Preclinical Data on ARQ 092, Demonstrating Effectiveness in the Treatment of Sickle Cell Disease Presented at ASH 2016
Celgene, Dana-Farber Cancer Institute, U of Arkansas for Medical Sciences Establish Myeloma Genome Project
AIXTRON Announced that President Obama Issued an Order on December 2, 2016 Prohibiting prohibiting the Acquisition of the U.S. Business of AIXTRON by Grand Chip Investment GmbH
Trillium Presents Initial Data From Ongoing Study of TTI-621 in Patients With Advanced Hematologic Malignancies at ASH 2016
bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent <BETA>-Thalassemia (TDT) and Severe Sickle Cell Disease at ASH 2016
Biogen Announces Data Reinforcing the Long-Term Safety and Efficacy of Extended Half-Life Hemophilia Therapies ELOCTATE and ALPROLIX at ASH 2016
Atara Bio Announces Results from Ongoing Phase 2 Trial of Allogeneic Cytomegalovirus-specific Cytotoxic T Lymphocytes at ASH 2016
Spark Therapeutics, Pfizer Present Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at ASH 2016
Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL at ASH 2016
Aduro Biotech Presents Preclinical Data Supporting Clinical Development of its Anti-APRIL Antibody, BION-1301, for Treatment of Multiple Myeloma at ASH 2016
Bellicum Announces Updated Clinical Data from BPX-501 Study in Children with Primary Immune Deficiencies and Hemoglobinopathies at ASH 2016
Alnylam Announces Positive Initial Clinical Activity Results for Givosiran (ALN-AS1) for Treatment of Acute Hepatic Porphyrias at ASH 2016
Alnylam Announces Positive Interim Phase 1 Results for Fitusiran in Hemophilia A and B Patients with Inhibitors at ASH 2016
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.
Be Your Own Boss
Tools & Features
Real Time Feed
Submit News Tips
Licensing and APIs
Apps (iOS and Android)
In the News
Terms and Conditions
1 (877) 440-9464 (ZING)
© Copyright Benzinga
Benzinga - Feed Your Mind